Back to Search Start Over

Cost-effectiveness of a patient-centred approach to managing multimorbidity in primary care: a pragmatic cluster randomised controlled trial.

Authors :
Thorn, Joanna
Man, Mei-See
Chaplin, Katherine
Bower, Peter
Brookes, Sara
Gaunt, Daisy
Fitzpatrick, Bridie
Gardner, Caroline
Guthrie, Bruce
Hollinghurst, Sandra
Lee, Victoria
Mercer, Stewart W.
Salisbury, Chris
Source :
BMJ Open; Jan2020, Vol. 10 Issue 1, p1-10, 10p
Publication Year :
2020

Abstract

Objective: Patients with multiple chronic health conditions are often managed in a disjointed fashion in primary care, with annual review clinic appointments offered separately for each condition. This study aimed to determine the cost-effectiveness of the 3D intervention, which was developed to improve the system of care. Design: Economic evaluation conducted alongside a pragmatic cluster-randomised trial. Setting; General practices in three centres in England and Scotland. Participants: 797 adults with three or more chronic conditions were randomised to the 3D intervention, while 749 participants were randomised to receive usual care. Intervention: The 3D approach: comprehensive 6-monthly general practitioner consultations, supported by medication reviews and nurse appointments. Primary and secondary outcome measures: The primary economic evaluation assessed the cost per quality-adjusted life year (QALY) gained from the perspective of the National Health Service (NHS) and personal social services (PSS). Costs were related to changes in a range of secondary outcomes (QALYs accrued by both participants and carers, and deaths) in a cost–consequences analysis from the perspectives of the NHS/PSS, patients/carers and productivity losses. Results: Very small increases were found in both QALYs (adjusted mean difference 0.007 (−0.009 to 0.023)) and costs (adjusted mean difference £126 (£−739 to £991)) in the intervention arm compared with usual care after 15 months. The incremental cost-effectiveness ratio was £18 499, with a 50.8% chance of being cost-effective at a willingness-to- pay threshold of £20 000 per QALY (55.8% at £30 000 per QALY). Conclusions: The small differences in costs and outcomes were consistent with chance, and the uncertainty was substantial; therefore, the evidence for the cost-effectiveness of the 3D approach from the NHS/PSS perspective should be considered equivocal. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20446055
Volume :
10
Issue :
1
Database :
Complementary Index
Journal :
BMJ Open
Publication Type :
Academic Journal
Accession number :
141711550
Full Text :
https://doi.org/10.1136/bmjopen-2019-030110